About Us

Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

A Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Social Media

Bluesky • Facebook • Instagram • LinkedIn • YouTube

Meet the Laser Focus World Team

Editorial

Sales

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology
My Watchlist
Indicators
Industrial Laser Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cardio Diagnostics Enters Into an Agreement with AGEPHA Pharma to Advance Precision Assessment and Management of Inflammation Associated with Coronary Heart Disease

By: via Business Wire

AGEPHA Pharma will supply LODOCO® (low-dose colchicine) for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ test to identify patients with inflammation-driven coronary heart disease (CHD)

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of epigenetics and AI, today announced an agreement with AGEPHA Pharma that will enable the validation of a precision-guided approach to treating inflammation-driven coronary heart disease (CHD). Specifically, AGEPHA Pharma will supply LODOCO® (low-dose colchicine), its FDA-approved anti-inflammatory medication, for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ blood test to identify patients with inflammation-driven coronary heart disease (CHD) and assess their response to LODOCO® over time.

Inflammation is increasingly recognized as a key driver to atherosclerosis and adverse cardiac events. Therefore, the clinical community is increasingly seeking more informative tools to guide targeted treatment approaches, especially for conditions like INOCA (Ischemia with No Obstructive Coronary Arteries), which is gaining attention for its inflammatory underpinnings and diagnostic complexity.

Cardio Diagnostics’ PrecisionCHD™ test is an AI-powered integrated genetic-epigenetic test to aid in the diagnosis and management of CHD. The six DNA methylation markers evaluated by the PrecisionCHD™ test map to modifiable drivers of CHD, including inflammation. For each patient, the PrecisionCHD™ test provides personalized insights into their specific molecular drivers that could help inform more targeted treatment and clinical decision making. This and the dynamic nature of DNA methylation make the PrecisionCHD™ test uniquely suited for non-invasive, repeatable monitoring of inflammation, offering a significant advantage over traditional imaging-based approaches.

Cardio Diagnostics is currently evaluating potential clinical sites for this study. The sponsored study will use PrecisionCHD™ to identify patients with inflammation-driven CHD who will be prescribed LODOCO® by a physician if clinically warranted. The patient will then be re-tested to examine changes in inflammation via DNA methylation signatures. The final study design will be outlined in partnership with the Principal Investigator of the clinical site(s) and registered as a clinical trial.

“This study reflects a precision medicine model where diagnosis and treatment are both guided by the patient’s unique molecular insights,” said Robert Philibert MD PhD, Chief Medical Officer at Cardio Diagnostics. “All interventions have potential adverse events. Fortunately, through the use of PrecisionCHD™, forward leaning clinicians can maximize the therapeutic index of cardiovascular treatment plans for their patients.”

This initiative follows broader scientific momentum, including the American Heart Association’s recent $15 million commitment to studying inflammation’s impact on cardiovascular and brain health, a sign of growing recognition of the need for precision tools in inflammation management.

About Cardio Diagnostics

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit https://cdio.ai/.

Forward-Looking Statements

Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result,” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, and dependence on results as discussed in the Annual Report on Form 10-K for the period ended December 31, 2024, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company’s financial performance and could cause the Company’s actual results for future periods to differ materially from any opinions or statements expressed within this press release.

“This study reflects a precision medicine model where diagnosis and treatment are both guided by the patient’s unique molecular insights."

Contacts

More News

View More
Lower Rates Put RV Stocks Back in the Fast Lane
Via MarketBeat
Tickers CWH THO WGO
Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Via MarketBeat
Topics Economy
Tickers HSY MDLZ PEP
Thor Industries Tracking for New Highs in 2026
Via MarketBeat
Topics Economy
Tickers THO
Cintas Stock Sends a Clear Buy Signal as Momentum Builds
Via MarketBeat
Topics Government
Tickers CTAS
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.